Marinus Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$13.2M
Doctors Paid
1,084
Transactions
4,307
2024 Total
$5.1M
Payment Breakdown by Category
Research$12.2M (92.6%)
Consulting$251,334 (1.9%)
Food & Beverage$88,021 (0.7%)
Travel$49,790 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.2M | 1,587 | 92.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $590,896 | 163 | 4.5% |
| Consulting Fee | $251,334 | 76 | 1.9% |
| Food and Beverage | $88,021 | 2,338 | 0.7% |
| Travel and Lodging | $49,790 | 131 | 0.4% |
| Education | $272.20 | 12 | 0.0% |
Payments by Type
Research
$12.2M
1,587 transactions
General
$980,313
2,720 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC OLE) | $2.8M | 0 | 719 |
| RAISE | $1.9M | 0 | 237 |
| A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus | $1.7M | 0 | 344 |
| A Phase 1 Multi Dose Open-Label Parallel Comparative Pharmacokinetics Study of Ganaxalone Hot Melt Extrusion Formulation | $826,538 | 0 | 7 |
| A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC) | $759,840 | 0 | 96 |
| A Phase 1 Single Dose Open-Label Crossover Comparative Bioavailability Study of Two Oral Formulations of Ganaxalone | $708,994 | 0 | 14 |
| A Phase 1, Randomized, Double-blind, Placebo- and Positive controlled, Parallel-arm Study with Nested Crossover to Investigate the Effects of Ganaxolone on the QT/QTc Interval in Healthy Subjects | $671,352 | 0 | 5 |
| A Phase 1 Multicenter Open-Label Parallel-Group Pharmacokinetic Single Dose Study of Ganaxalone in Adult Subjects with Normal and Impaired Hepatic Function | $652,158 | 0 | 13 |
| Marinus Pharmaceuticals, Inc._HME-MAD_Ganaxolone_NDA_Kansas_22-7709 | $562,635 | 0 | 3 |
| TSC 3001 | $555,926 | 0 | 15 |
| A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment | $534,033 | 0 | 92 |
| A Phase 1 Open-Label Fixed-Sequence Drug-Drug Interaction Study to Evaluate the Effect of Multiple Doses of Cannabidiol on the Pharmacokinetics of Ganaxalone in Healthy Adult Participants | $292,291 | 0 | 6 |
| 1042-TSC-3001 | $110,613 | 0 | 7 |
| A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy Followed by Long-term Open-label Treatment. | $93,542 | 0 | 13 |
| 1042-TSC-3002 | $25,721 | 0 | 2 |
| A Study to Optimize the Dosing Regimen and Assess Safety and Efficacy of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus | $24,804 | 0 | 7 |
| Marinus Pharmaceuticals, Inc._DDI (drug-drug interaction)_Ganaxolone_NDA__23-6699 | $5,000 | 0 | 1 |
| Marinus Pharmaceuticals, Inc._Palatability_Ganaxolone_NDA_Undetermined_22-7731 | $5,000 | 0 | 1 |
| Expanded Access With Adjunctive Ganaxolone Treatment in Children and Young Adults With Cyclin Dependent Kinase-like 5 Deficiency Disorder | $1,575 | 0 | 1 |
| Randomized Therapy In Status Epilepticus (RAISE) | $1,134 | 0 | 3 |
| 1042-SE-2002 | $625.00 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 44
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Fraquania Freeman, Aprn, APRN | Primary Care | Tyler, TX | $14.34 | $0 |
| Anas Alshawa, Md, MD | Neurology | Chicago, IL | $14.22 | $0 |
| Adam Ammar, M.d, M.D | Neurological Surgery | Morristown, NJ | $14.21 | $0 |
| Dr. Amanda Ayala, Md, MD | Physical Medicine & Rehabilitation | Morristown, NJ | $14.21 | $0 |
| Dr. Roger Silverstein, Md, MD | Pediatrics | Bingham Farms, MI | $14.05 | $0 |
| Robert Coryell, Md, MD | Pediatrics | Salt Lake City, UT | $13.54 | $0 |
| Angela Liberatore, Np, NP | Pediatrics | Portland, OR | $13.54 | $0 |
| Michelle Quyen Nguyen, Np, NP | Registered Nurse | Rocklin, CA | $13.44 | $0 |
| Dr. Samuel Puckett, M.d, M.D | Pediatrics | Newport, TN | $12.08 | $0 |
About Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. has made $13.2M in payments to 1,084 healthcare providers, recorded across 4,307 transactions in the CMS Open Payments database. In 2024, the company paid $5.1M. The top product by payment volume is ZTALMY ($679,494).
Payments were distributed across 65 medical specialties. The top specialty by payment amount is Internal Medicine ($370,888 to 11 doctors).
Payment categories include: Food & Beverage ($88,021), Consulting ($251,334), Research ($12.2M), Travel & Lodging ($49,790).
Marinus Pharmaceuticals, Inc. is associated with 1 products in the CMS Open Payments database.